INMD Stock Recent News
INMD LATEST HEADLINES
Expects Q2 Revenue Between $86.2M-$86.3M, Pro-Forma Revenue (including new platform pre-orders) Between $102.4M-$102.5M, Decreases FY 2024 Guidance to $430M-$440M Conference call to be held on Thursday, Aug. 1, 2024, at 8:30 a.m. Eastern Time YOKNEAM, Israel, July 11, 2024 /PRNewswire/ -- InMode Ltd.
Shareholders of InMode Ltd. have seen a 46% decline in value due to slowing sales and capital allocation uncertainties. Sales growth has been impacted by rising interest rates affecting leasing deals, leading to lower revenue growth projections for 2024. The company's new share repurchase program should reverse the dilution shareholders previously experienced.
YOKNEAM, Israel , May 16, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer and Spero Theodorou MD, Chief Medical Officer, will present in-person at the Jefferies Healthcare Conference in New York on June 5, 2024.
InMode (INMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In the most recent trading session, InMode (INMD) closed at $20.62, indicating a +0.05% shift from the previous trading day.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Recently, Zacks.com users have been paying close attention to InMode (INMD). This makes it worthwhile to examine what the stock has in store.
The latest trading day saw InMode (INMD) settling at $21.61, representing a +1.93% change from its previous close.
InMode (INMD) concluded the recent trading session at $21.23, signifying a -0.05% move from its prior day's close.
Zacks.com users have recently been watching InMode (INMD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.